ADENTRA (TSE:ADEN – Get Free Report) had its price target cut by analysts at Scotiabank from C$43.00 to C$33.00 in a research report issued on Monday,BayStreet.CA reports. The firm currently has an “outperform” rating on the stock.
Other research analysts have also recently issued reports about the company. National Bankshares decreased their price objective on ADENTRA from C$60.00 to C$53.00 and set an “outperform” rating on the stock in a report on Monday, March 17th. Stifel Nicolaus lowered their price target on ADENTRA from C$41.00 to C$36.00 and set a “buy” rating for the company in a report on Thursday, April 17th. Cormark reduced their price objective on shares of ADENTRA from C$55.00 to C$46.00 in a report on Monday, March 17th. CIBC lowered their target price on shares of ADENTRA from C$44.00 to C$34.00 and set an “outperform” rating for the company in a research note on Tuesday, April 22nd. Finally, Desjardins set a C$46.00 price objective on shares of ADENTRA and gave the stock a “buy” rating in a report on Wednesday, April 16th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $45.11.
Check Out Our Latest Stock Report on ADEN
ADENTRA Trading Down 1.7 %
About ADENTRA
Adentra Inc is a distributor of architectural products to fabricators, home centers and professional dealers servicing the new residential, repair and remodel, and commercial construction end markets. The company operates a network in North America of 86 facilities in the United States and Canada.
Further Reading
- Five stocks we like better than ADENTRA
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3 Mid-Cap Medical Stocks Outperforming the Market
- What Are the FAANG Stocks and Are They Good Investments?
- The Top-Ranked Insider Buys From April by Market Cap
- Growth Stocks: What They Are, What They Are Not
- Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Receive News & Ratings for ADENTRA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADENTRA and related companies with MarketBeat.com's FREE daily email newsletter.